# Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

> **NCT02231710** · PHASE1 · TERMINATED · sponsor: **Bellicum Pharmaceuticals** · enrollment: 1 (actual)

## Conditions studied

- Primary Immune Deficiency Disorders
- Hemophagocytic Lymphohistiocytosis
- Inherited Bone Marrow Failure Syndrome
- Hemoglobinopathies
- Metabolic Disorders

## Interventions

- **BIOLOGICAL:** BPX-501 and Rimiducid

## Key facts

- **NCT ID:** NCT02231710
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2015-09
- **Final completion:** 2018-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** due to lack of enrollment and changes to the sponsor development portfolio
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231710, "Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02231710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*